Welcome to the 2nd Annual Mitochondria Targeted Drug Development Summit
The 2nd annual Mitochondria-Targeted Drug Development Summit returns as the only industry-led meeting focused on overcoming the challenge of treating unmet medical needs caused by mitochondrial dysfunction.
Explore success stories from leading experts overcoming common challenges whilst exploring what’s next to help you accelerate your pipeline into the clinic.
With 20+ hours of content, 2 interactive workshops and over 5 hours of networking with key industry leaders from Astellas/Mitobridge, Minovia Therapeutics, Stealth Biotherapeutics, GenSight Biologics and many more, this comprehensive forum will completely focus on accelerating the discovery and development of novel drugs that target mitochondrial functions.
Make this your 2022 must-attend meeting and virtually network with 80+ senior CSOs, CEOs, research scientists, academics and investors committed to targeting mitochondria to tackle challenges with developing therapies for primary mitochondrial diseases, muscular dystrophy, metabolic disorders & neurodegenerative diseases. Continue your search for therapeutics for various medical conditions associated with mitochondrial dysfunction.
In this focused summit, you’ll learn from leading pioneers who’ll be sharing their experience on:
Overcoming challenges with Clinically Validated Endpoints, Pre-clinical Animal Models, Clinical Trial Design and Precision Medicine
The Use of Gene Therapy, Editing Technology & Innovation
The Role of Ex Vivo Mitochondrial Transfer to Improve Stem Cell Therapy Outcomes (Mitochondrial Transfusion)
The Relationship of Mitochondrial DNA (mtDNA) Mutations/Damage & Mitochondrial Reactive Oxygen Species (ROS) Dysfunction
The Current Progress of Mitochondrial Quality Control (MQC) Signaling Pathways Mitochondrial Biogenesis, Mitochondrial Dynamics, and Mitochondrial Autophagy (Mitophagy)
How to Examine the Oxidative Phosphorylation (OXPHOS) System/ Lipid (per) Oxidation of the Mitochondria